Adaptive Biotechnologies (NASDAQ:ADPT) Shares Gap Up – What’s Next?

Adaptive Biotechnologies Corporation (NASDAQ:ADPT)’s share price gapped up before the market opened on Friday . The stock had previously closed at $12.45, but opened at $13.05. Adaptive Biotechnologies shares last traded at $12.9250, with a volume of 592,085 shares.

Analyst Ratings Changes

ADPT has been the topic of a number of recent analyst reports. Wall Street Zen lowered Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a research note on Saturday, March 7th. Piper Sandler set a $21.00 price target on Adaptive Biotechnologies in a research note on Friday, February 6th. BTIG Research upped their price objective on shares of Adaptive Biotechnologies from $21.00 to $22.00 and gave the company a “buy” rating in a research note on Friday, February 6th. Morgan Stanley started coverage on shares of Adaptive Biotechnologies in a report on Monday, December 1st. They set an “equal weight” rating and a $21.00 price objective on the stock. Finally, Guggenheim raised their target price on shares of Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock a “buy” rating in a research report on Monday, January 26th. Seven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $18.25.

Adaptive Biotechnologies Stock Performance

The company has a market capitalization of $1.98 billion, a PE ratio of -32.27 and a beta of 2.19. The business has a fifty day moving average price of $16.61 and a 200 day moving average price of $15.85.

Adaptive Biotechnologies (NASDAQ:ADPT) last issued its earnings results on Thursday, February 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.10. Adaptive Biotechnologies had a negative return on equity of 46.68% and a negative net margin of 21.48%.The business had revenue of $71.68 million during the quarter, compared to analysts’ expectations of $59.38 million. During the same quarter in the previous year, the business earned ($0.23) EPS. The company’s revenue for the quarter was up 51.0% on a year-over-year basis. Research analysts forecast that Adaptive Biotechnologies Corporation will post -0.92 earnings per share for the current fiscal year.

Insider Buying and Selling at Adaptive Biotechnologies

In related news, CEO Chad M. Robins sold 53,083 shares of the firm’s stock in a transaction dated Tuesday, March 3rd. The stock was sold at an average price of $15.52, for a total transaction of $823,848.16. Following the sale, the chief executive officer directly owned 1,934,247 shares in the company, valued at approximately $30,019,513.44. This trade represents a 2.67% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Harlan S. Robins sold 14,233 shares of the stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an average price of $16.52, for a total transaction of $235,129.16. Following the completion of the sale, the insider directly owned 1,155,291 shares of the company’s stock, valued at $19,085,407.32. This trade represents a 1.22% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 1,209,806 shares of company stock valued at $19,656,239 in the last quarter. Company insiders own 6.40% of the company’s stock.

Institutional Investors Weigh In On Adaptive Biotechnologies

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ADPT. Caitong International Asset Management Co. Ltd acquired a new position in Adaptive Biotechnologies in the 4th quarter worth $28,000. Sound Income Strategies LLC acquired a new stake in shares of Adaptive Biotechnologies during the third quarter valued at about $30,000. EverSource Wealth Advisors LLC increased its position in shares of Adaptive Biotechnologies by 197.1% during the fourth quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock worth $38,000 after acquiring an additional 1,565 shares during the last quarter. Assetmark Inc. lifted its stake in shares of Adaptive Biotechnologies by 867.9% in the fourth quarter. Assetmark Inc. now owns 3,020 shares of the company’s stock worth $49,000 after acquiring an additional 2,708 shares in the last quarter. Finally, T. Rowe Price Investment Management Inc. acquired a new position in shares of Adaptive Biotechnologies in the fourth quarter worth about $51,000. Hedge funds and other institutional investors own 99.17% of the company’s stock.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.